π¬ Milvexian trial fails to cut CV events after ACS
The Phase 3 LIBREXIA ACS trial did not show that adding milvexian reduced cardiovascular events following acute coronary syndrome (ACS). This study involved 14,194 patients across 44 countries, with final results presented at the ESC Congress 2026. CV death, MI, or stroke was 5.4% in the milvexian group versus 5.1% in the placebo group. Despite demonstrating expected anticoagulation, the drug failed to significantly lower MACE on top of standard antiplatelet therapy. Future trials, like LIBREXIA AF, are examining higher doses in different conditions. π¬